Drug intelligence / Profile preview

Reduced Intensity Conditioning-New York Medical College-Hodgkin lymphoma

Development stage: Unknown
Lead developer: Takeda
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

Reduced Intensity Conditioning-New York Medical College-Hodgkin lymphoma refers to a specific clinical trial protocol (NCT02588612) designed for children, adolescents, and young adults with high-risk or relapsed/refractory CD30+ Hodgkin lymphoma. The regimen involves a reduced intensity conditioning (RIC) phase using chemotherapy agents such as fludarabine, busulfan, melphalan, or cyclophosphamide to prepare the patient for an allogeneic stem cell transplantation (AlloSCT). Following the transplant, patients receive brentuximab vedotin (Adcetris) as a targeted consolidation therapy. Brentuximab vedotin is an antibody-drug conjugate (ADC) that binds to CD30 on the surface of Hodgkin lymphoma cells, internalizes, and releases the potent microtubule-disrupting agent monomethyl auristatin E (MMAE), leading to cell cycle arrest and apoptosis. This multi-modal approach aims to leverage the graft-versus-lymphoma effect of the transplant while minimizing toxicity through reduced-intensity conditioning and enhancing efficacy with targeted biologic therapy.

Brand names: Adcetris
Other names: Brentuximab Vedotin Post-AlloSCT in CD30+ Hodgkin LymphomaA Multicenter Pilot Study of Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Targeted Immunotherapy in Children, Adolescents and Young Adults With Poor Risk CD30+ Hodgkin Lymphoma

Beyond the preview

Go deeper on Reduced Intensity Conditioning-New York Medical College-Hodgkin lymphoma.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reduced Intensity Conditioning-New York Medical College-Hodgkin lymphoma.

Explore the full profile